Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Releasing the Brakes: Quantitative Cell-based Bioassays to Advance Individual and Combination Immune Checkpoint Immunotherapy

Part # PS362


Jamison Grailer, Julia Gilden, Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

A major challenge in the development of antibody-based biologics drugs is access to quantitative and reproducible functional bioassays. Existing methods rely on primary cells and measurement of complex functional endpoints that are cumbersome, variable, and often fail to yield data quality required for drug development in a quality-controlled environment. We have developed a portfolio of functional cell-based reporter bioassays to measure the activity of biologics drugs designed to target immune checkpoint receptors including co-inhibitory (e.g., PD-1, CTLA-4, LAG-3) and costimulatory (e.g., 4-1BB, GITR, OX40) receptors. These bioassays consist of stable cell lines that express luciferase under the precise control of receptor-mediated intracellular signals. Here we describe the application of MOA-based immune checkpoint coinhibitory receptor bioassays for biologics drug discovery, development, potency and stability studies.

Printed in USA.